The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year.

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for ... the market for Gilead Sciences ...

Nicole Randall, 37, also agreed to forfeit roughly $4 million in proceeds from the sale of the drugs, including four ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Dr Reddy’s Laboratories reports 2% increase in net profit, attributing growth to new acquisitions and product launches.

Dr. Reddy's Laboratories Limited RDY reported third-quarter fiscal 2025 earnings of 20 cents per American Depositary Share ...

Fund managers don’t often consider religion when making investment decisions, even if they can sometimes seem like the product of a wing and a prayer. But they are missing a very visible hand that has ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...